SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation around potential rescheduling of marijuana following reports of a planned executive order. The community is discussing the possibility of a major uptrend, potential short squeezes, and analysts updating their target prices. Some traders express caution, pointing to reverse splits and past disappointments.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom ($AVGO) is trending as investors digest the company's earnings report and forward guidance, with community sentiment split between bullish expectations for new ATHs and concerns about potential profit-taking. Discussions revolve around the impact of AI chip revenue and gross margins on the stock's valuation. Analyst target price upgrades are anticipated, adding to the bullish outlook for some traders.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending due to a volatile trading day, with community members discussing a potential pump and dump scheme following a recent reverse split and subsequent offering. The stock's price experienced a significant surge and then a sharp decline, leading to debates about the company's fundamentals and market manipulation. Traders are actively speculating on whether MIGI can regain compliance with listing requirements and if further dilution is expected.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending as investors discuss the company's recent Q3 earnings, which included revenue growth and raised guidance, alongside the unexpected announcement of the CEO's departure in 2026. The community is actively debating the impact of these factors, with some anticipating analyst upgrades and a potential rally, while others express concerns about the future direction of the company amid leadership transition. A significant share buyback program has also fueled bullish sentiment, signaling confidence in Lululemon's trajectory.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as it showcases its in-house autonomy and AI technology at its first-ever Autonomy and AI Day, with community members discussing the potential impact of new AI-driven features and hardware on the company's future. Investors are weighing Rivian's strategy to develop its own chips and compete with Tesla's autonomous driving capabilities, while some express concerns about the timeline for implementation and the capital expenditure required. There are mixed opinions about the stock's potential, with some anticipating a significant rise and others remain cautious given the company's current financial position.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending as investors await key data and FDA feedback, with anticipation building around potential outcomes for Pemvidutide in MASH and obesity. Bullish community members express confidence in the science and potential buyout scenarios, while bears highlight concerns about trial results and data interpretation. The discussion also includes speculation around competitor data, potential partnership deals, and upcoming announcements.

AXIL Brands, Inc. engages in the manufacture, market, sale and distribution of hearing and audio enhancement, and protection products. It operates through the Hearing Enhancement and Protection, and Hair Care and Skin Care segments. The Hearing Enhancement and Protection segment includes ear buds, earmuffs, ear plugs, outdoor speakers, and ear care items. The Hair Care and Skin Care segment focuses on expanding its business-to-business salon sales through its network of domestic and international distributors. The company was founded on May 21, 2015 and is headquartered in Beverly Hills, CA.

AXIL Brands Inc.

AXIL Brands is trending due to a thin-float technical breakout, attracting momentum traders, with the community actively discussing overnight price action and potential for further gains. Community members are also pointing to a recent distribution agreement with Walmart as a longer-term catalyst. Traders are closely watching for offering news.

The GEO Group, Inc. engages in the design, financing, development, and support services for secure facilities, processing centers, and community re-entry facilities. It operates through the following segments: U.S. Secure, Electronic Monitoring and Supervision, Reentry, and International Services. The U.S. Secure Services segment encompasses the United States-based public-private partnership corrections and detention business. The Electronic Monitoring and Supervision Services segment conducts its services in the U.S. The Reentry Services Segment consists of various community-based and reentry services. The International Services segment consists of public-private partnership secure services operations in Australia and South Africa. The company was founded by George C. Zoley in 1984 and is headquartered in Boca Raton, FL.

Geo Group, Inc.

GEO Group is trending amid discussions around immigration enforcement, detention facilities, and the potential impact of government policies. Community perspectives are sharply divided, with some anticipating gains from increased ICE activity and others expressing ethical concerns and criticizing the company's business practices. The conversation also involves potential contract opportunities and the company's financial health.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences ($GLSI) is trending due to anticipation surrounding potential news related to its breast cancer treatment, with speculation focused on the SABCS conference. The community is exhibiting FOMO based on hints of positive data, and some believe shorts may be covering their positions. GLSI is seen as a promising healthcare stock, particularly for women, given its potential for high efficacy.

Frontdoor, Inc. engages in the provision of home service plans. Its home service plans cover the repair or replacement of major home’s systems and appliances. The firm’s service focuses on water heaters, garbage disposals, doorbells, smoke detectors, ceiling fans, central vacuums, refrigerators, dishwashers and trash compactors. Its brands include American Home Shield, HSA, OneGuard and Landmark. The company was founded on January 2, 2018, and is headquartered in Memphis, TN.

Frontdoor Inc.

$FTDR is trending as traders discuss recent trade alerts and potential bullish trends, while noting overbought conditions based on RSI. The community is also evaluating the stock's position relative to its moving averages and key resistance levels like the 60-day high. Overall sentiment appears mixed, balancing short-term profit-taking with longer-term growth potential in the home services sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

InflaRx N.V. (NASDAQ:IFRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of InflaRx N.V. (NASDAQ:IFRX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six ratings firms that are covering the stock, Marketbeat.com reports. One...

Is InflaRx NV Gaining or Losing Market Support?

FY2026 EPS Estimates for InflaRx Raised by Cantor Fitzgerald

InflaRx N.V. (NASDAQ:IFRX - Free Report) - Investment analysts at Cantor Fitzgerald lifted their FY2026 earnings per share estimates for InflaRx in a report released on Tuesday, November 11th. Cantor...

FY2025 EPS Estimates for InflaRx Reduced by HC Wainwright

InflaRx N.V. (NASDAQ:IFRX - Free Report) - Stock analysts at HC Wainwright decreased their FY2025 earnings estimates for InflaRx in a report released on Monday, November 10th. HC Wainwright analyst...

InflaRx (NASDAQ:IFRX) Announces Quarterly Earnings Results, Hits Estimates

InflaRx (NASDAQ:IFRX - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates...

Stock Traders Purchase High Volume of Call Options on InflaRx (NASDAQ:IFRX)

InflaRx N.V. (NASDAQ:IFRX - Get Free Report) was the recipient of some unusual options trading on Monday. Stock investors bought 2,819 call options on the company. This represents an increase of...

Guggenheim Boosts InflaRx (NASDAQ:IFRX) Price Target to $22.00

Guggenheim upped their price objective on shares of InflaRx from $10.00 to $22.00 and gave the company a "buy" rating in a research note on Monday...

<ul class="summary-bullets"><li>The mid-stage study aimed to evaluate the safety and pharmacokinetic/pharmacodynamic profile of INF904.</li><li>Over four weeks of therapy in patients with HS, the company observed rapid and clinically meaningful reductions in inflammatory signs and substantial reductions in patient-reported pain scores in the study.&nbsp;</li><li>No safety concerns were identified in either of the two patient categories, the company said. &nbsp;</li></ul>InflaRx N.V. (IFRX) announced on Monday that data from a mid-stage trial of its INF904 in certain skin conditions demonstrated positive outcomes, including a reduction in disease severity and pain, which sent shares rallying 62% in the pre-market session.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.inflarx.de/Home/Investors/Press-Releases/11-2025-InflaRx-Reports-Positive-Phase-2a-Data-for-INF904-in-Hidradenitis-Suppurative--HS--and-Chronic-Spontaneous-Urticaria--CSU-.html">studied</a> the experimental drug in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU). It was aimed at evaluating the safety and pharmacokinetics / pharmacodynamics profile of INF904.While Hidradenitis suppurativa (HS) is a chronic skin disease that causes painful, boil-like lumps to form under the skin, Chronic spontaneous urticaria (CSU) is a skin condition characterized by recurrent, itchy hives (wheals) and/or swelling (angioedema) that lasts for six weeks or longer.The company said that the data provide a strong rationale for further development of the drug in both these diseases. &nbsp;<h2 class="st-heading-2">Mid-Stage Trial Results</h2>Over four weeks of therapy in patients with HS, the company observed rapid and clinically meaningful reductions in inflammatory signs and substantial reductions in patient-reported pain scores in the study.&nbsp;In CSU, the company observed substantial reductions in the 7-day Urticaria Activity Score (UAS7) broadly across patients, particularly among those with severe disease. Urticaria Activity Score (UAS) is a patient-reported tool used to measure the severity of chronic hives (urticaria) by assessing the number of hives and the intensity of itch daily.No safety concerns were identified in either of the two patient categories, the company said.The company is now looking forward to initiating a Phase 2b trial in HS in 2026, while also engaging in dialogue with possible collaborators to advance the drug in CSU.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IFRX">IFRX stock</a> remained within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.IFRX stock is down 50% this year and by about 20% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/grab-holdings-to-take-equity-interest-in-remote-driving-tech-startup/cLPcKrSRE2c">Grab Deepens Autonomous Mobility Push With $60 Million Investment In Vay</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

IFRX Stock Soars Pre-Market After Experimental Drug Shows Promise In Treating Chronic Skin Diseases

The company said that the data provide a strong rationale for further development of the drug in Hidradenitis Suppurative and Chronic Spontaneous Urticaria.

Equity

InflaRx (NASDAQ:IFRX) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of InflaRx from a "hold" rating to a "sell" rating in a research report on Saturday...

InflaRx (IFRX) to Release Earnings on Friday

InflaRx (NASDAQ:IFRX) will be releasing its Q3 2025 earnings before the market opens on Friday, November 14. (View Earnings Report at...

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.

InflaRx N.V.

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.17	--	--	N/A
Q3 '25	-$0.21	--	--	N/A
Q2 '25	-$0.22	-$0.24	-13.19%	MISSED
Q1 '25	-$0.21	-$0.15	27.54%	BEAT
Q4 '24	-$0.17	--	--	N/A

IFRX
InflaRx N.V.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest IFRX News

IFRXInflaRx N.V.